Objective-Unreliable antibodies often hinder the accurate detection of an endogenous protein, and this is particularly true for the cardiac and smooth muscle cofactor, MYOCD (myocardin). Accordingly, the mouse Myocd locus was targeted with 2 independent epitope tags for the unambiguous expression, localization, and activity of MYOCD protein. Approach and Results-3cCRISPR (3-component clustered regularly interspaced short palindromic repeat) was used to engineer a carboxyl-terminal 3×FLAG or 3×HA epitope tag in mouse embryos. Western blotting with antibodies to each tag revealed a MYOCD protein product of ≈150 kDa, a size considerably larger than that reported in virtually all publications. MYOCD protein was most abundant in some adult smooth muscle-containing tissues with surprisingly low-level expression in the heart. Both alleles of Myocd are active in aorta because a 2-fold increase in protein was seen in mice homozygous versus heterozygous for FLAG-tagged Myocd. ChIP (chromatin immunoprecipitation)-quantitative polymerase chain reaction studies provide proof-of-principle data demonstrating the utility of this mouse line in conducting genome-wide ChIP-seq studies to ascertain the full complement of MYOCD-dependent target genes in vivo. Although FLAG-tagged MYOCD protein was undetectable in sections of adult mouse tissues, low-passaged vascular smooth muscle cells exhibited expected nuclear localization. 
T he trustworthy detection, localization, and interactive association of a protein are essential in understanding cellular processes under normal and pathological conditions. Yet, biology is plagued by fallacious antibodies, 1 particularly, those directed against transcription factors.
2 Accordingly, antibodies to a variety of epitope tags have been developed to circumvent the difficulties often encountered with monoclonal or polyclonal antibodies. 3 Epitope tagging is commonplace in laboratories using plasmids to study ectopic protein expression. Far fewer examples exist with the tagging of endogenous protein-coding gene loci in mice, [4] [5] [6] likely because of the labor-intensive approach of traditional gene targeting. However, the CRISPR-Cas9 (clustered regularly interspaced short palindromic repeat-associated protein 9) genome-editing system [7] [8] [9] has revolutionized the production of novel mouse strains, including those carrying epitope tags. 10, 11 Here, we present the accurate expression, localization, and binding activity of epitope-tagged MYOCD (myocardin), an SRF (serum response factor) cofactor 12 that powerfully drives the program of vascular smooth muscle cell (VSMC) differentiation. [13] [14] [15] [16] 
Materials and Methods
Data available on request from the authors.
Three-Component CRISPR Editing of the Myocd Locus
For the Myocd 3×FLAG mouse, single guide RNA (sgRNA) of sequence ACAGCAGUGGUAAACACCCG (synthesized in vitro as described 17 ) was tested for activity in a split reporter assay 18 ( Figure  IIB in the online-only Data Supplement) and injected (50 ng/µl) with Cas9 mRNA (100 ng/μL; TriLink Biotechnologies) and a symmetrical, single-strand oligonucleotide containing the 3×FLAG sequence (100 ng/μL; Ultramer PAGE-purified; Integrated DNA Technologies) into the pronucleus of C57BL/6J zygotes. The single-strand oligonucleotide was of the same strand as the sgRNA so as to prevent hybridization of the two in the embryo. For the Myocd 3×HA mouse, synthetic sgRNA (same as above) and CAS9 protein (both from Synthego) were validated for DNA cleavage in an in vitro tube assay as described by the manufacturer. CAS9 protein and sgRNA were mixed (3 pmol each) as a ribonucleoprotein complex and then combined with a 249 single-strand Megamer oligonucleotide (100 ng/μL; Integrated DNA Technologies) before cytoplasmic injection. Viable 2-cell stage embryos were transferred to pseudopregnant C57BL/6J females.
Local Institutional Animal Care and Use Committees approved all mouse studies.
Mouse Pup Genotyping, Off-Targeting, and Breeding
One-week-old founder pups were toe-clipped or ear-punched, and tissue was digested overnight at 55°C in lysis buffer (50 mmol/L KCl, 10 mmol/L Tris-HCl [pH 9], 0.1% Triton X-100, and 0.2 mg/mL proteinase K) on an interval mixer. The next morning, samples were heated at 95°C for 10 minutes to inactivate the proteinase K and spun down at 15 000g for 10 minutes. Each sample of DNA (1 μL) was mixed with 12 μL nuclease-free water, 10 μL AccuStart II Supermix (Quantabio), and 1 μL each of forward and reverse primers ( Table I in Off-targeting was assessed initially with CCTop, 19 CasOFFinder, 20 and the MIT CRISPR website 21 and later with the CRISPOR tool. 22 No predicted off-targets were found within 2 megabases of the on-target double-strand break. We selected the top 9 distal off-target sites based on an aggregate analysis of each prediction program. PCR primers flanking each predicted off-target site were synthesized (Integrated DNA Technologies) and used to amplify genomic DNA from founder mice as above only the number of PCR cycles was limited to 28. Each primer pair contained linker sequences positioned at the 5' end of the template-specific primer sequence necessary for next-generation sequencing; the forward primers contained the linker sequence, ACACTGACGACATGGTTCTACA, and the reverse primers contained the linker sequence, TACGGTAGCAGAGACTTGGTCT. After the initial 28-cycle PCR reaction, the samples were verified on an agarose gel, and approximately equal amounts were subjected to a second PCR reaction (8 cycles only) using primers containing Illumina adaptor sequence, 10 bp sample-specific barcodes, and the original linker sequences. Amplified sequences were then submitted to the Genomics Core for next-generation sequencing on an Illumina HiSeq 2500 platform. This setup allowed for all 9 amplicons to be sequenced in 1 lane of the sequencer. Raw sequence reads were analyzed for indels with CRISPResso. 23 Positive founder mice derived from CRISPR-Cas9 genome editing are mosaic. 11, 24 We, therefore, backcrossed each positive founder to C57BL/6J mice for Sanger sequencing to confirm germline transmission of each epitope tag. Sanger sequencing of F 1 mice confirmed germline transmission of the correct allele, as well as sequence fidelity in and around the edited region. Myocd 3×FLAG was successfully bred through the germline (in 2 founders), and data were similar in both lines. We confirmed 1 mosaic founder carrying the Myocd 3×HA tag, but the line was lost because of dystocia of the pregnant founder. We nevertheless isolated tissues for Western ( Figure 1B ) and limited immunofluorescence microscopy of adult tissues (data not shown). Each of the CRISPR-edited mouse lines is listed in the Major Resources 
Western Blot
Tissues (from male and female mice, aged 6-10 weeks) were isolated and homogenized in 200 μL of cell lysis buffer (Cell Signaling, no. 9803). After brief centrifugation, supernatants were transferred to fresh 1.5 mL microfuge tubes for protein quantification with DC protein assay kit (Bio-Rad, no. 5000111). Samples were boiled in LDS sampling buffer (Invitrogen, no. NP0007) and subjected to electrophoresis in SDS-PAGE gel. Proteins were transferred to a polyvinylidene difluoride membrane for 2 hours in cold room at 80 V using a Trans-blot machine (Bio-Rad). Membranes were then blocked with 5% nonfat milk in TBS-T (Tris-buffered saline containing 0.1% Tween 20) for 1 hour and incubated with primary antibody for 1 hour at room temperature. After washing, secondary antibodies were incubated for 1 hour at room temperature followed by immersion in chemiluminescence substrate (Thermo Fisher, no. 34080) and exposed to X-ray film. A list of antibodies used is provided in the Major Resource Table in the online-only Data Supplement.
Chromatin Immunoprecipitation
At least 5 mouse aortae were isolated and fixed in 10 mL of 4% paraformaldehyde at room temperature for 10 minutes. One mL of 1.25 mol/L glycine was added to stop crosslinking. Aortae were washed twice with 1×PBS and 1 mL of ChIP (chromatin immunoprecipitation) lysis buffer (50 mmol/L Tris-HCl [pH 8.0], 150 mmol/L NaCl, 5 mmol/L EDTA, 0.1% deoxycholate, 1% Triton X-100, and protease inhibitor cocktail) was added. Tissues were then pulse-sonicated (intervals of 10 s pulse for 2 minutes) and centrifuged at 12 000g for 10 minutes at 4°C. Supernatants were collected and transferred to fresh 1.5 mL microfuge tubes. Mouse anti-FLAG antibody (SigmaAldrich, no. F3165) and mouse IgG were added to lysate (≈500 μL each) respectively and incubated for 2 hours at 4°C. One-hundred microliters of Dynabeads protein G (Thermo Fisher, no. 10003D) were washed twice with 1×PBS and resuspended in the original volume of ChIP lysis buffer for each ChIP reaction. Magnetic beads were mixed with antibody-lysate and incubated for 2 hours at 4°C. After 5 washes with ChIP lysis buffer, samples were treated with proteinase K (10 mg/mL) at 55°C on a thermomixer for 1 hour. DNA was then recovered and purified by boiling with Chelex-100 resin (Bio-Rad, no. 1422822) for downstream assays, (eg, real-time qPCR).
Isolation and Culture of Mouse Aortic Smooth Muscle Cells
We followed a previously published protocol for isolating mouse aortic SMC. 25 In brief, for each independent experiment, 3 mouse aortae were isolated and placed into ice-cold Hank's balanced salt solution in a 15 mL conical tube. Aortae were digested with 3 mL of buffer A (10 mg collagenase II, 10 mg soybean trypsin inhibitor in 10 mL Hank's balanced salt solution) at 37°C for 20 minutes. Aortae were then transferred into clean culture dishes loaded with 10 mL buffer B (DMEM/F12 medium with 20% FBS and 1% Pen-Strep, prewarmed to 37°C). The adventitial layer was peeled off using fine forceps, and aortae were transferred into another clean culture dish with 10 mL buffer B. Each aorta was then cut longitudinally, and the intimal layer was scraped with angled blunt forceps to remove endothelial cells. Aortae were cut with fine scissors into 1 to 2 mm pieces and transferred to 1 well of a 6-well culture plate with 3 mL buffer C (3 mL buffer B+67 μL elastase [Worthington, no. LS002279] at 24.8 mg/mL). Tissues were incubated for 15 minutes at 37°C followed by repeated pipetting with cut 1 mL tips to loosen cells. Cells were incubated another 15 minutes at 37°C and dissociated cells were repeat pipetted with uncut 1 mL tip 5 to 6×. The digestion mixture was transferred to a clean 15 mL canonical tube and 3 mL buffer A was added to stop digestion. Samples were centrifuged at 800g for 5 minutes at 4°C to pellet cells. Cells were resuspended in 5 mL buffer A and plated in a well of 6-well plate. Isolated mouse smooth muscle cells were studied on reaching 50% to 70% confluency.
Confocal Microscopy
Mouse aortic smooth muscle cells were cultured on 22×22 mm coverslips in 6-well plates. Cells were fixed with 4% paraformaldehyde for 10 minutes at room temperature. Coverslips were rinsed in 1×PBS twice and cells permeabilized with 1×PBS containing 0.1% Triton X-100 on an ice bath. Cells were blocked with 3% BSA for 20 minutes at room temperature, and anti-FLAG primary antibody (Sigma-Aldrich, no. F1804; 1:100 dilution) was applied at room temperature for 40 minutes. Coverslips were rinsed twice with 1×PBS and cells incubated with fluorescence-conjugated secondary antibodies (1:200) for 40 minutes at room temperature. Cells were then mounted with ProLong Gold antifade reagent with DAPI (4',6-diamidino-2-phenylindole, dihydrochloride; Thermo Fisher, no. P36935) and examined with an Olympus IX81 confocal microscope using uniform settings for all conditions.
Flow Cytometry
Aortae derived from the mTmG/Myh11CreER T2 cross were digested as mentioned above, and freshly dissociated mouse aortic smooth muscle cells were resuspended in PBS and submitted to the University of Rochester Medical Center Flow Cytometry Core. Cells were sorted according to the Tomato (610 nm) or GFP (green fluorescent protein; 510 nm) signal and quantitated as a percentage of total cells stained for GFP or Tomato.
Transfection Assays
Rat aortic smooth muscle cells (A7r5, ATCC CRL-1444) were transfected with either Myocd short intervening RNA (si-Myocd, catalog no. SASI_Rn01_00118674, Sigma-Aldrich) or MISSION siRNA Universal Negative Control (si-Scramble, catalog no. SIC001; SigmaAldrich). Cells were mixed with DharmaFECT1 transfection reagent (Lipofectamine 2000, catalog no. T2001-02; Dharmacon) in a 1:1 ratio followed by incubation at room temperature for 20 minutes. Cell mixtures were then added to the wells of cell plates followed by incubation for 48 hours at 37°C. After incubation, cells were washed twice with ice-cold PBS, scraped, and collected in either NP-40 lysis buffer (50 mmol/L Tris-HCl [pH 7.4], 150 mmol/L NaCl, 0.5% Nonidet P-40) containing EDTA-free complete protease and phosphatase inhibitor (Sigma-Aldrich/Roche) for protein estimation or Qiazol buffer for mRNA measurement. For protein measurement, 20 μg samples were run on SDS-PAGE gels, transferred to nitrocellulose membrane, blocked with 4% nonfat milk, and subsequently incubated with TUBA1A (anti-α-tubulin, catalog no. sc5286; Santa Cruz), or MYOCD (catalog no. ab22073; Abcam), followed by incubation with secondary antibodies and detection using SuperSignal West Pico Chemiluminescent Substrate (catalog no. 34080; Thermo Fisher Scientific) on autoradiography film. For Myocd mRNA levels total RNA was extracted from aorta and bladder using a Qiagen miRNeasy kit (catalog no. 217004). Input RNA quality and concentration were measured using a Synergy HT Take3 Microplate Reader (BioTek, Winooski, VT), and cDNA was prepared using SuperScript IV VILO Master Mix (catalog no. 11756500, Invitrogen). qPCR was performed in triplicate using TaqMan Fast Advanced Master Mix (catalog no. 44-445-57) in an Mx3000p Real-Time PCR System (Stratagene, Santa Clara, CA). The primers for Myocd (Assay ID no. Rn01786178) were purchased from Thermo Fisher Scientific/TaqMan. Results of mRNA expression were normalized to internal control Gapdh, and relative mRNA expression was determined using the ΔΔCt method.
Nano-Liquid Chromatography-Tandem Mass Spectrometry
Rat aorta, urinary bladder, and A7r5 cells were homogenized and lysed in lysis buffer (50 mmol/L Tris-HCl [pH 7.4], 150 mmol/L NaCl, 0.5% Nonidet P-40) containing EDTA-free complete protease and phosphatase inhibitor (Sigma-Aldrich/Roche). Protein levels were measured using Bradford assays (Bio-Rad), after which 30 μg samples were run on SDS-PAGE gels followed by fixing the gel (50% methanol and 10% acetic acid) for 40 minutes at room temperature and washing for 1 hour. Bands corresponding to 100 kDa were cut and subjected to mass spectrometry analysis. The proteins were eluted and analyzed using liquid chromatography-tandem mass spectrometry (Applied Biomics, Hayward, CA). Nano-liquid chromatography fractionation and matrix-assisted laser desorption ionization-time of flight/time of flight were followed by a standard search of the National Center for Biotechnology Information and SwissProt databases using MASCOT. The ≈150 kDa FLAG-tagged MYOCD band from mouse bladder was similarly processed and analyzed.
Statistical Analyses
Primary data were assessed for normality with a Shapiro-Wilk test for equal variance (in case of 1-or 2-way ANOVA), and all datasets displayed normal distributions and variances. Accordingly, we used parametric paired t test for comparisons between experimental and control conditions or 1-and 2-way ANOVA for multiple group comparisons. All data analysis was performed in GraphPad Prism 7. Results are expressed as mean±SD. A value of P<0.05 was considered statistically significant. For mendelian inheritance of different alleles we used a χ 2 test.
Results

In Vivo MYOCD Protein Expression and Binding Activity
There are at least 4 MYOCD isoforms with predicted molecular weights of 106 kDa (v1, 983 amino acids), 101 kDa (v2, 935 amino acids), 97 kDa (v3, 904 amino acids), and 92 kDa (v4, 856 amino acid). 26, 27 Most commercial antibodies report endogenous MYOCD protein of ≈100 kDa, consistent with the predicted molecular weights of each isoform. However, on knockdown of Myocd mRNA, there was no corresponding change in a widely assumed MYOCD protein band in A7r5 SMC, mouse and rat aorta and bladder, mouse aortic SMC, and human coronary artery SMC ( Figure IB in the online-only Data Supplement and data not shown). Similar results were found using a different siRNA to Myocd in mouse aortic smooth muscle cell ( Figure  IC in the online-only Data Supplement). Mass spectrometry of the excised 100 kDa bands from rat aorta and bladder, as well as the A7r5 SMC line, revealed no evidence of MYOCD peptides (Table II in the online-only Data Supplement). Thus, although many commercial antibodies are able to reveal ectopic MYOCD expression (not shown), there is a question as to the accuracy of detecting the endogenous MYOCD protein.
Accordingly, 3-component CRISPR 11 was used to target the last coding exon of Myocd with either 3×FLAG or 3×HA epitope tags ( Figure IIA in the online-only Data Supplement). Correct targeting was validated by Sanger sequencing in 3×FLAG (4/35), and 3×HA (1/6) founders with no predicted off-targeting in linkage disequilibrium with the on-target site; sequence analysis of the top 9 predicted distal off-target sites showed no mutations, consistent with the high specificity of the sgRNA (data not shown). The Myocd 3×FLAG allele was bred through the germline, and sibling-matings revealed an expected mendelian ratio ( Figure IID in the online-only Data Supplement). Western blotting supported biallelic expression of the Myocd gene ( Figure 1A) . The estimated molecular weight of FLAG-tagged MYOCD was ≈150 kDa, a size considerably larger than that reported in the literature; Myocd 3×HA mice showed a similar sized band ( Figure 1B ). An independently generated Myocd myc-HA mouse also revealed MYOCD to have a molecular mass of ≈150 kDa ( Figure IIIA in the online-only Data Supplement). Adult tissue profiling showed the highest expression of MYOCD in bladder and uterus with moderate levels in the aorta; surprisingly lower levels of MYOCD protein were consistently seen in the adult heart ( Figure 1C and Figure IIIB in the online-only Data Supplement). Importantly, mass spectrometry analysis of the 150 kDa band revealed small quantities of MYOCD protein (Table III in the online-only Data Supplement). ChIP-qPCR of Myocd 3×FLAG aortic tissue showed significant enrichment of SRF-binding CArG sequences around several known targets of the SRF-MYOCD transcriptional switch ( Figure 1D ). Despite repeated efforts under numerous experimental conditions, no consistent MYOCD signal was obtained on tissue sections with an array of antibodies to FLAG (data not shown). These in vivo findings reveal a higher molecular weight of MYOCD than previously reported and define, for the first time, reliable detection of endogenous MYOCD protein expression and binding activity in adult mouse tissues.
In Vitro MYOCD Protein Expression
The mTmG reporter mouse 28 was crossed with the Myh11CreER T2 mouse 29 to indelibly mark VSMC of the aortic wall with GFP. Most aortic cells from passage numbers 1 to 4 are GFP+; however, beginning at passage number 5 a notable decrease in GFP+ VSMC was seen ( Figure IV in the onlineonly Data Supplement). Thus, in vitro studies were restricted to cultures of mouse VSMC at passage 1 to 3. Homozygous Myocd 3×FLAG VSMC exhibited similar mRNA levels of SRF/ MYOCD target genes as in wild-type VSMC, suggesting the FLAG epitope tag did not adversely affect MYOCD activity ( Figure 
Discussion
We introduce new myocd mouse models wherein epitope tags (3×FLAG and 3×HA) were used to independently target the last coding exon of the Myocd locus. The motivation for generating these mice stems from our long-standing difficulty in assessing endogenous levels of MYOCD protein expression in vivo or in vitro in mouse, human, and rat. 30 The initial characterization of the epitope-tagged mice reported here reveals several notable findings. First, the 2-fold increase in MYOCD protein expression of homozygous versus heterozygous Myocd 3×FLAG mice indicates biallelic gene transcription. Second, multiple epitope tags demonstrate the molecular weight of the endogenous MYOCD protein to be much higher (≈150 kDa) than formerly reported. Indeed, with rare exception, 31 the molecular weight of MYOCD protein, when reported, has been between 95 to 105 kDa. We show in data from 2 independent laboratories, using distinct reagents and cell types, that a putative MYOCD protein of ≈100 kDa does not change with siRNA knockdown of Myocd mRNA. We, therefore, caution investigators using commercial antibodies to MYOCD and urge rigorous analysis to authenticate the specificity of bands so as to avoid further confusion in the field. The higher molecular weight of MYOCD over its predicted size of ≈100 kDa likely reflects several post-translational modifications shown previously to occur in MYOCD, at least in cultured model systems. 30, 32 Precision CRISPR editing of key amino acids undergoing post-translational modification in the Myocd 3×FLAG mouse may clarify the higher-than-expected molecular weight of MYOCD and reveal more nuanced phenotypes than those reported in conditional Myocd knockouts of the heart and vessel wall. 33, 34 Lower molecular weight bands were seen with FLAG antibodies, particularly in aorta, bladder, and uterus ( Figure 1 and Figures III and V in the online-only Data Supplement). The identity of these bands is unknown at this time, but they could represent different MYOCD isoforms, differential post-translational modifications of a specific MYOCD isoform, or proteolytic cleavage products of MYOCD. The targeting of the C terminus of MYOCD with epitope tags, as reported here, should allow for the detection and functional assessment, via precision CRISPR editing, of all previously described MYOCD isoforms. 26, 27 Another noteworthy result was the low-level MYOCD protein in adult heart. This finding was seen in every experiment conducted and cannot be attributed to lower mRNA levels because we originally reported Myocd mRNA to be equivalent in heart and aorta, 13 a finding we have repeated here ( Figure  VI in the online-only Data Supplement). The lower levels of MYOCD protein in adult heart, as compared to bladder and aorta, could reflect a known mechanism of microRNAmediated repression during cardiac development. Such repression was shown to promote cardiomyocyte maturation while repressing the VSMC gene program. 35, 36 Interestingly, Myocd mRNA is elevated in heart failure, 37 a condition characterized by the re-emergence of the fetal heart gene program, which includes an array of VSMC genes. Thus, it seems that levels of MYOCD protein are under exquisite control in the normal adult heart for optimal cardiac function.
The use of a FLAG antibody in ChIP-qPCR studies provides proof-of-principle data supporting ChIP-seq studies in the vessel wall under normal or stress-induced conditions. In this context, a growing number of SRF-independent target genes of MYOCD have been reported. 30 The ability to generate mice in which each Myocd allele carries either a 3×FLAG or 3×HA tag offers a rigorous approach to define novel DNA binding sequences and the corresponding DNA-binding transcription factors associated with MYOCD. The mice reported here will also be useful for the discovery of new MYOCD binding proteins or RNAs, especially the class of long noncoding RNA. These and other studies will further illuminate MYOCD biology, thus providing a more integrative understanding of how this cofactor functions under normal and pathological conditions.
In contrast to adult tissues, nuclear-localized MYOCD was observed consistently in cultured VSMC as demonstrated in siRNA knockdown studies. Previous mouse studies showed FLAG-tagged protein expression in tissue sections 38 suggesting there may be some steric hindrance in detecting the MYOCD protein in vivo. It is possible the epitope is masked through interactions of MYOCD with other molecules in the cell. 30, 32 However, we have observed consistent staining in adult mouse tissues carrying an inducible HA-tagged Myocd transgene (unpublished), and preliminary staining of aorta carrying the Myocd 3×HA tag suggests that it could be a more discriminating epitope tag than 3×FLAG for immunostaining, though this will require further analysis. Importantly, genetically marked VSMC progressively decrease from culture indicating the need for careful experimental design and circumspect conclusions drawn from in vitro primary VSMC experiments.
The CRISPR revolution has expedited the generation of new mouse models. 11 We anticipate similarly tagged mice, as those reported here, will be developed for rigorous protein analyses and accelerated discoveries in vascular biology.
